Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review-Reference-Cited by-同舟云学术

Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review

Published:2014-04-03 Issue:5 Volume:47 Page:287-306
ISSN:0891-6934
Container-title:Autoimmunity
language:en
Short-container-title:Autoimmunity

Author:

Sozzani Silvano,Abbracchio Maria P.,Annese Vito,Danese Silvio,De Pità Ornella,De Sarro Giovambattista,Maione Sabatino,Olivieri Ignazio,Parodi Aurora,Sarzi-Puttini Piercarlo

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.3109/08916934.2014.897333

Reference156 articles.

1. Management of the Patient Receiving Parenteral Biologic Therapy

2. Which are the antibodies to watch in 2013?

3. Tumor necrosis factor as a therapeutic target of rheumatologic disease

4. Drug Insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease

5. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CURCUMA AERUGINOSA ROXB. EXTRACT INHIBITS THE PRODUCTION OF PROINFLAMMATORY CYTOKINES ON RAW 264.7 MACROPHAGES;International Journal of Applied Pharmaceutics;2024-02-15

2. Musculin does not modulate the disease course of Experimental Autoimmune Encephalomyelitis and DSS colitis;Immunology Letters;2023-03

3. Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases;Autoimmunity;2022-04-28

4. IN VIVO INVESTIGATION OF ANTIDIABETIC, HEPATOPROTECTIVE, ANTI-INFLAMMATORY AND ANTIPYRETIC ACTIVITIES OF CENTAUREA TOUGOURENSIS BOISS. & REUT;J PHYSIOL PHARMACOL;2021

5. Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials;ACR Open Rheumatology;2020-07-25